Name No. For Patients with Purpose
MelMarT-II 20-37

with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin.

The purpose of this study is that there is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life.


Name No. For Patients with Purpose
R3767-ONC-2011 22-26

with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

The purpose of this study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a “study drug” or called “study drugs” when combined). The study is focused on patients with a type of skin cancer known as melanoma.


Name No. For Patients with Purpose
R3767-ONC-2055 22-25

Either stage IIC, III, or stage IV per American Joint Committee on Cancer (AJCC) 8th edition and have histologically confirmed melanoma that is completely surgically resected.

The purpose of this study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by relapse free survival (RFS).


Name No. For Patients with Purpose
MK-7684A-010/​KEYVIBE-010 22-28

resected, IO naïve, high risk stage IIB, IIC, III and IV Melanoma.

The purpose of this trial is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS).


Name No. For Patients with Purpose
MK-3475-630/KEYNOTE-630 CTRIAL-IE 20-08


This is a randomized study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing recurrence free survival (RFS).


Name No. For Patients with Purpose
R2810-ONC-1788 18-50

Cutaneous Squamous Cell Carcinoma (High Risk)

The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery and radiation therapy (RT).